Compare JYNT & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | NKTX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 132.8M |
| IPO Year | 2014 | 2020 |
| Metric | JYNT | NKTX |
|---|---|---|
| Price | $9.74 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $17.00 | $13.25 |
| AVG Volume (30 Days) | 56.3K | ★ 873.9K |
| Earning Date | 03-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,176,002.00 | N/A |
| Revenue This Year | $5.65 | N/A |
| Revenue Next Year | $3.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.47 | N/A |
| 52 Week Low | $7.50 | $1.31 |
| 52 Week High | $13.47 | $2.74 |
| Indicator | JYNT | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 42.66 |
| Support Level | $9.37 | $1.91 |
| Resistance Level | $10.22 | $2.27 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 38.42 | 8.70 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.